sur BIOMERIEUX (EPA:BIM)
BioMérieux to Present Strategic Plans at J.P. Morgan HealthCare Conference
bioMérieux, a leading name in in vitro diagnostics, will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. This conference will occur from January 13 to 16, 2025. Pierre Boulud, bioMérieux's CEO, is scheduled to present on January 14 at 5:15 pm PT.
During his presentation, Boulud will outline the company's strategic plan, GO•28, focusing on profitable and sustainable growth. Targets include achieving a +7% CAGR in organic sales from 2024 to 2028 and increasing the CEBIT margin from 16.6% in 2023 to 20% by 2028.
Updates on product installations, with 500 new BIOFIRE® units and 900 SPOTFIRE® units in Q4 2024, will be shared. Additionally, Boulud will discuss bioMérieux's recent acquisition of SpinChip, a Norwegian start-up specializing in point-of-care immunoassays.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BIOMERIEUX